Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer

被引：2
|
作者：
Lee, Nathan V. [1 ]
Yuan, Jing [1 ]
Eisele, Koleen [1 ]
Cao, Joan Q. [1 ]
Painter, Cory L. [1 ]
Chionis, John [1 ]
Liu, Chaoting [1 ]
Shields, David J. [1 ]
Kan, Julie L. C. [1 ]
Arndt, Kim [2 ]
VanArsdale, Todd [1 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] Pfizer Inc, Pearl River, NY USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-LB-136
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-136
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PALBOCICLIB: CDK4/6 INHIBITION IN THE TREATMENT OF ER-POSITIVE BREAST CANCER
    Owsley, J.
    Jimeno, A.
    Diamond, J. R.
    DRUGS OF TODAY, 2016, 52 (02) : 119 - 129
  • [2] Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
    Portman, Neil
    Alexandrou, Sarah
    Carson, Emma
    Wang, Shudong
    Lim, Elgene
    Caldon, C. Elizabeth
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : R15 - R30
  • [3] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Neil Portman
    Heloisa H. Milioli
    Sarah Alexandrou
    Rhiannon Coulson
    Aliza Yong
    Kristine J. Fernandez
    Kee Ming Chia
    Ensar Halilovic
    Davendra Segara
    Andrew Parker
    Sue Haupt
    Ygal Haupt
    Wayne D. Tilley
    Alex Swarbrick
    C. Elizabeth Caldon
    Elgene Lim
    Breast Cancer Research, 22
  • [4] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Lim, Elgene
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, KeeMing
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, Elizabeth C.
    Portman, Neil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 110 - 110
  • [5] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Portman, Neil
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, Kee Ming
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, C. Elizabeth
    Lim, Elgene
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [6] DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Nanda, Sarmistha
    Shea, Martin J.
    Schiff, Rachel
    Osborne, C. Kent
    Rimawi, Mothaffar
    Fu, Xiaoyong
    CANCER RESEARCH, 2023, 83 (05)
  • [7] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [8] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
  • [9] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    María Jimena Rodriguez
    María Cecilia Perrone
    Marina Riggio
    Marta Palafox
    Valeria Salinas
    Andrés Elia
    Natali Daiana Salgueiro
    Andrea Eugenia Werbach
    María Paula Marks
    Marcelo A. Kauffman
    Luciano Vellón
    Violeta Serra
    Virginia Novaro
    Scientific Reports, 13
  • [10] Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors
    Cruz, Marcelo R.
    Limentani, Kimberly
    Taxter, Timothy
    Santa-Maria, Cesar A.
    Behdad, Amir
    Gradishar, William J.
    Nagy, Rebecca J.
    Cristofanilli, Massimo
    CANCER RESEARCH, 2018, 78 (04)
12345